BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang HL, Lu X, Yang X, Xu N. Effectiveness and safety of daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: Systematic review and meta-analysis. J Gastroenterol Hepatol. 2017;32:45-52. [PMID: 27597318 DOI: 10.1111/jgh.13587] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
Number Citing Articles
1 Haga H, Sato H, Koseki A, Saito T, Okumoto K, Hoshikawa K, Katsumi T, Mizuno K, Nishina T, Ueno Y. A machine learning-based treatment prediction model using whole genome variants of hepatitis C virus. PLoS One. 2020;15:e0242028. [PMID: 33152046 DOI: 10.1371/journal.pone.0242028] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
2 Fujii H, Umemura A, Nishikawa T, Yamaguchi K, Moriguchi M, Nakamura H, Yasui K, Minami M, Tanaka S, Ishikawa H, Kimura H, Takami S, Nagao Y, Shima T, Itoh Y. Real-world efficacy of daclatasvir and asunaprevir with respect to resistance-associated substitutions. World J Hepatol 2017; 9(25): 1064-1072 [PMID: 28951778 DOI: 10.4254/wjh.v9.i25.1064] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
3 Meanwell NA, Belema M. The Discovery and Development of Daclatasvir: An Inhibitor of the Hepatitis C Virus NS5A Replication Complex. In: Sofia MJ, editor. HCV: The Journey from Discovery to a Cure. Cham: Springer International Publishing; 2019. pp. 27-55. [DOI: 10.1007/7355_2018_47] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
4 Koshino K, Ushigome H, Masuda K, Matsuyama T, Harada S, Nakamura T, Nobori S, Iida T, Yoshimura N. Effective Treatment With Daclatasvir and Asunaprevir in Kidney Transplant Patients Infected With Hepatitis C Virus: A Report of Two Cases. Transplant Proc 2017;49:1053-5. [PMID: 28583525 DOI: 10.1016/j.transproceed.2017.03.051] [Reference Citation Analysis]
5 Jang ES, Kim KA, Kim YS, Kim IH, Lee BS, Lee YJ, Chung WJ, Jeong SH. Real-life effectiveness and safety of the daclatasvir/asunaprevir combination therapy for genotype 1b chronic hepatitis C patients: An emphasis on the pretreatment NS5A resistance-associated substitution test. J Med Virol 2019;91:2158-65. [PMID: 31452206 DOI: 10.1002/jmv.25575] [Reference Citation Analysis]
6 Lee HW, Yoo KY, Won JW, Kim HJ. Direct Acting Antiviral Agents in Korean Patients with Chronic Hepatitis C and Hemophilia Who Are Treatment-Naïve or Treatment-Experienced. Gut Liver 2017;11:721-7. [PMID: 28874040 DOI: 10.5009/gnl17209] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
7 Ichikawa T, Miyaaki H, Miuma S, Taura N, Motoyoshi Y, Akahoshi H, Nakamura J, Takahashi Y, Honda T, Yajima H, Uehara R, Hino N, Narita S, Tanaka H, Sasaki S, Nakao K. Changes in serum LDL, PCSK9 and microRNA-122 in patients with chronic HCV infection receiving Daclatasvir/Asunaprevir. Biomed Rep 2019;10:156-64. [PMID: 30906544 DOI: 10.3892/br.2019.1189] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
8 Suzuki F, Hatanaka N, Bando E, Nakamura K, Komoto A. Safety and effectiveness of daclatasvir and asunaprevir dual therapy in patients with genotype 1 chronic hepatitis C: results from postmarketing surveillance in Japan. Hepatol Int 2018;12:244-53. [DOI: 10.1007/s12072-018-9872-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
9 Wu B, Wang Z, Xie Q. Cost-effectiveness of novel regimens for Chinese patients with chronic hepatitis C. Curr Med Res Opin. 2019;35:847-857. [PMID: 30409038 DOI: 10.1080/03007995.2018.1546678] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
10 Marcellin F, Roux P, Protopopescu C, Duracinsky M, Spire B, Carrieri MP. Patient-reported outcomes with direct-acting antivirals for the treatment of chronic hepatitis C: current knowledge and outstanding issues. Expert Rev Gastroenterol Hepatol 2017;11:259-68. [PMID: 28116926 DOI: 10.1080/17474124.2017.1285227] [Cited by in Crossref: 5] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
11 Korean Association for the Study of the Liver (KASL). 2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C. Clin Mol Hepatol 2018;24:169-229. [PMID: 30092624 DOI: 10.3350/cmh.2018.1004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
12 Liu Y, Wang Z, Tobe RG, Lin H, Wu B. Cost Effectiveness of Daclatasvir Plus Asunaprevir Therapy for Chinese Patients with Chronic Hepatitis C Virus Genotype 1b. Clin Drug Investig. 2018;38:427-437. [PMID: 29417464 DOI: 10.1007/s40261-018-0621-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
13 Oh JY, Kim BS, Lee CH, Song JE, Lee HJ, Park JG, Hwang JS, Chung WJ, Jang BK, Kweon YO, Tak WY, Park SY, Jang SY, Suh JI, Kwak SG. Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world. Korean J Intern Med 2019;34:794-801. [PMID: 29792020 DOI: 10.3904/kjim.2017.368] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Fujii H, Kimura H, Kurosaki M, Hasebe C, Akahane T, Yagisawa H, Kato K, Yoshida H, Itakura J, Sakita S, Satou T, Okada K, Kusakabe A, Kojima Y, Kondo M, Morita A, Nasu A, Tamada T, Okushin H, Kobashi H, Tsuji K, Joko K, Ogawa C, Uchida Y, Mitsuda A, Sohda T, Ide Y, Izumi N. Efficacy of daclatasvir plus asunaprevir in patients with hepatitis C virus infection undergoing and not undergoing hemodialysis: Daclatasvir plus asunaprevir in non-HD and HD patients. Hepatol Res 2018;48:746-56. [DOI: 10.1111/hepr.13070] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
15 Ishigami M, Hayashi K, Honda T, Kuzuya T, Ishizu Y, Ishikawa T, Nakano I, Urano F, Kumada T, Yoshioka K. Daclatasvir and asunaprevir treatment in patients infected by genotype 1b of hepatitis C virus with no or subtle resistant associated substitutions (RAS) in NS5A-Y93. J Med Virol. 2018;90:736-744. [PMID: 29111616 DOI: 10.1002/jmv.24978] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]